Research paper

Access route selection for percutaneous coronary intervention among Vietnamese patients: Implications for in-hospital costs and outcomes

Hoa T.T. Vu, Richard Norman, Ngoc M. Pham, Hung M. Pham, Hoai T.T. Nguyen, Quang N. Nguyen, Loi D. Do, Rachel R. Huxley, Crystal M.Y. Lee, Tu M. Hoang, Christopher M. Reid

Thai Nguyen University of Medicine and Pharmacy, Thai Nguyen, Vietnam
School of Public Health, Curtin University, Perth, Australia
Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
Vietnam National Heart Institute, Hanoi, Vietnam
Faculty of Health, Deakin University, Melbourne, Australia
The George Institute for Global Health, University of New South Wales, Sydney, Australia
School of Psychology and Public Health, La Trobe University, Melbourne, Australia
Thai Nguyen University of Medicine and Pharmacy, Thai Nguyen, Vietnam

ARTICLE INFO

Article history:
Received 29 October 2020
Revised 1 February 2021
Accepted 7 February 2021
Available online 2 March 2021

Keywords:
Percutaneous coronary intervention
Hospital cost
Outcomes
Vietnam

ABSTRACT

Background: Little is known about rates of access site (transradial (TRI) or transfemoral (TFI)) preference for percutaneous coronary intervention (PCI) and in-hospital costs of patients undergoing these procedures in lower-and middle-countries. Here, we report on access site use, in-hospital costs and outcomes of patients undergoing PCI in Vietnam.

Methods: Information from 868 patients were included in the cohort of 1022 patients recruited into the first PCI registry in Vietnam. The total hospital costs and in-hospital outcomes of patients undergoing TRI and TFI were compared. Hospital costs were obtained from the hospital admission system, and major adverse cardiac events, major bleeding events and length of stay were identified through review of medical records.

Findings: TRI was the dominant access site for interventionists (694/868 patients). The TFI group reported more lesions of the left main artery, more previous coronary artery bypass grafts and previous PCI in comparison with the TRI group (all p < 0.05). The TRI group was associated with a lower overall cost of admission (the adjusted difference was -1526.3 USD, 95% confident interval CI (-1996.2; -1056.3)), shorter length of hospital stay (-2 days, CI (-2.8; -1.2)) and lower rates of major bleeding post-procedure. Procedural factors such as radial access site, left main disease, PCI ≥2 stents, and PCI ≥ 2 lesions having the most impact on the in-hospital cost of patients undergoing PCI.

Interpretations: Among patients undergoing PCI, TRI was associated with lower costs and favourable clinical outcomes relative to TFI.

Funding: This research received partial financial support from Curtin University, Australia.

© 2021 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Research in context

• Evidence before this study: Choosing the optimal access location for percutaneous coronary intervention (PCI) has been controversial for many years. Despite accumulating studies on the differences between trans-radial access

https://doi.org/10.1016/j.lanwpc.2021.100116
2666-6065/© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
2.1. Methods

Methods

Access to PCI varies greatly by region. It is unclear that the evidence from these cost evaluations can be generalized to other countries, especially those less economically developed for which there are limited data, and potentially very significant differences in standards of care. Investigating the cost-saving for PCI procedures is also crucial in those countries as it can contribute to reducing the very high economic burden of CHD patients and potentially reform the current PCI practices. Being aware of the cost differences in clinical practice, cardiac interventionists can make their choices about access routes of PCI to reduce the financial burden on patients and healthcare systems.

In Asia, where CHD is the leading cause of death [89], the use of PCI for CHD patients is of growing interest in the region [10]. The widespread use of TRI in PCI procedures has been documented in recent studies [711], while the impact of PCI access sites on hospital cost and procedural outcomes has not been adequately reported. This paper uses data from the first PCI registry in Vietnam, assessed in-hospital costs and post-procedural outcomes according to access sites and identified potential factors associated with in-hospital costs among patients undergoing PCI.

2.2. In-hospital cost and outcomes

The primary outcome was total in-hospital costs from the day of admission to discharge. Our cost data were obtained from the hospital admission system and classified under the following categories: PCI costs (guide wire, IVUS, balloons and stents); medication costs; examination/laboratory costs; hospital bed costs; operation costs (electrocardiogram in the ward and angiography); and medical supplies (syringes and needles).

In-hospital outcomes were defined as major adverse cardiac events (MACE), major bleeding events and length of stay (LOS, measured in days). MACE was a composite of in-hospital death, myocardial infarction, and coronary revascularisation. Bleeding events were classified by the Bleeding Academic Research Consortium-BARC (2) indicating bleeding into five types according to clinical, laboratory, imaging evidence and health care required. Major bleeding was defined as BARC 3. Medical records were extracted to document these in-hospital outcomes.

2.3. Statistical analysis

Categorical variables (e.g., clinical, procedures, cost outcomes) were presented as numbers and percentages, while continuous variables were expressed as mean ± SD unless otherwise specified. Unlike the randomized clinical trials, the choice of access point in real-world practice is often based on numerous factors, including patients’ clinical characteristics and prognostic factors, therefore characteristics of study participants according to the two access sites were compared to see if there were any differences, using chi-square or Fisher exact tests and Independent samples t-test as appropriate. Median in-hospital costs and LOS were compared between TRI and TFI with the Mann-Whitney U test, the unadjusted and adjusted differences were obtained by Median regressions. Characteristic variables with statistical significance (p-value < 0.05) were selected for adjusting the cost differences. Logistic regression analyses were undertaken for two binary outcomes (major bleeding and MACE). Costs were converted into US Dollars, based on June 2019 exchange rates where 1USD = 23,350 Vietnamese Dong. These costs were then log transformed due to the likely skew in cost data, and the normality of this logged data was explored by both graphical and analytical methods such as skewness, kurtosis, box plot, Shapiro-Wilk and Kolmogorov-Smirnov test [14]. Multiple linear regressions were performed to identify the influence of different independent variables on the independent variable-log total in-hospital cost. Independent variables included age (year, continuous), sex (male vs. female), level of support from healthcare insurance (>80 and ≤80%), acute coronary syndrome (yes vs. no), hypertension (yes vs. no), diabetes (yes vs. no), current smoking (yes vs. no), prior stroke (yes vs. no), prior coronary artery bypass grafting (CABG) (yes vs. no), prior PCI (yes vs. no); transradial PCI (yes vs. no), left ventricular ejection fraction (<40% vs. patients undergoing PCI at VNHI in the same period. Briefly, information on demography, cardiac status, procedure, and in-hospital cost of the participants was recorded by interviewing patients, extracting medical records, reading procedural discs and exploring the admission system. From the total pool of patients, those who underwent ≥1 PCI (n = 78) were excluded, as it is difficult to attribute the bleeding events to a single procedure with certainty. Patients with cardiogenic shock (n = 11) and those with missing cost data (n = 66) were also excluded as these groups were associated with extremely high outlier costs or no information on total cost, respectively. When ≥1 entry location was used in one PCI, the primary access site was the one allowing the completion of the procedure. After these exclusions, our study population consisted of 868 patients with 694 TRIs and 174 TFIs.
Table 1
Clinical and procedural characteristics of the study population.

| Age (year), mean ± SD | TRI (n = 694) | TF (n = 174) | P value |
|-----------------------|--------------|-------------|---------|
| Male                  | 68.3 ± 9.7   | 69.3 ± 10.6 | 0.209<sup>†</sup> |
| Percentage of health insurance (HI) support | 469 (67.6) | 117 (67.2) | >0.999 |
| Non-HI                | 13 (1.9)     | 4 (2.3)     | 0.337 |
| <60%                  | 24 (3.5)     | 2 (1.1)     |        |
| 60-80%                | 133 (19.2)   | 39 (22.4)   |        |
| >80%                  | 524 (75.5)   | 129 (74.1)  |        |
| BMI ≥ 23.0 kg/m²      | 264 (38.0)   | 73 (42.0)   | 0.390 |

**Presentation**

- ST-elevation myocardial infarction: TRI = 93 (13.4); TF = 18 (10.3) (p = 0.341).
- Non-ST-elevation myocardial infarction: TRI = 105 (15.1); TF = 24 (13.8) (p = 0.746).
- Unstable angina: TRI = 165 (23.8); TF = 42 (24.1) (p = 0.999).
- Non-acute coronary syndrome: TRI = 331 (47.7); TF = 90 (51.7) (p = 0.386).

**Medical history**

- Hypertension: TRI = 462 (66.6); TF = 122 (70.1) (p = 0.423).
- Diabetes mellitus: TRI = 191 (27.5); TF = 59 (33.9) (p = 0.116).
- Hyperlipidaemia: TRI = 209 (30.1); TF = 62 (35.6) (p = 0.189).
- Current smoking: TRI = 75 (10.8); TF = 19 (10.9) (p = >0.999).
- Prior cerebral vascular disease: TRI = 94 (13.5); TF = 25 (14.4) (p = 0.874).
- Prior peripheral vascular disease: TRI = 4 (0.6); TF = 2 (1.1) (p = 0.761).
- Previous CABG: TRI = 4 (0.6); TF = 5 (2.9) (p = 0.024).
- Transradial intervention: TRI = 218 (31.4); TF = 75 (43.1) (p = 0.005).

**Tests prior to PCI**

- Left ventricular ejection fraction <40%: TRI = 68 (11.1); TF = 14 (8.9) (p = 0.513).
- Moderate to severe renal impairment<sup>b</sup> or left main disease (yes vs. no): TRI = 12 (1.7); TF = 6 (3.4) (p = 0.268).

**Procedural characteristics**

- Left main disease: TRI = 45 (6.5); TF = 35 (20.1) (p = <0.001).
- Restenotic lesions: TRI = 30 (4.3); TF = 11 (6.3) (p = 0.478).
- PCI with ≥ 2 lesions: TRI = 49 (7.1); TF = 11 (6.3) (p = 0.860).
- PCI with ≥ 2 stents: TRI = 257 (37.0); TF = 76 (43.7) (p = 0.127).
- Drug-eluting stent use: TRI = 683 (100.0); TF = 168 (100.0) (p = 0.871).
- Balloon only: TRI = 7 (1.0); TF = 2 (1.1) (p = 0.871).
- Intravascular ultrasound: TRI = 28 (4.0); TF = 12 (6.9) (p = 0.13).

<sup>a</sup> Independent samples T test.
<sup>b</sup> Creatinine > 200 μmol/L; Otherwise were Fisher exact or chi-square tests; TRI = Transradial intervention; TF = Transfemoral intervention; BMI = body mass index; CABG = Coronary artery bypass grafts.

≥40%), moderate to severe renal impairment (yes vs. no), intravascular ultrasound (yes vs. no), left main disease (yes vs. no), PCI with ≥ 2 lesions (yes vs. no), PCI with ≥ 2 stents (yes vs. no), major bleeding (yes vs. no), and MACE (yes vs. no). Variables with p < 0.1 in univariate regression analyses were included in the multivariable regression model. To assess potential predictors of in-hospital costs percentage changes were computed by exponentiating unstandardized coefficients and subtracting one from the resultant number and multiplying by 100. Relative importance of possible predictors of total hospital costs was evaluated using standardised regression coefficients. Subgroup analyses according to the presence or absence of acute coronary syndromes (ACS) were also conducted to evaluate cost and outcome differences. All p-values were two-tailed with statistical significance being defined as p ≤ 0.05.

All statistical analyses were performed in SPSS (SPSS Version 20.0 for Windows; SPSS Inc., Chicago, IL).

### 2.4. Ethics approval

The study received ethical approval from the Curtin University Human Research Ethics Committee (HRE 2017-0378) and Vietnam National Heart Institute provided reciprocal approvals for the study to be conducted and data analysed in Australia. A Patient Information Sheet was provided for every participant, which described clearly the purpose of the study, activities and rights of participants. It was voluntary to participate in the study and it is the right of participants to decline their participation or withdraw from the study via an ‘opt-out’ consent. The withdraw could occur at any time without any consequence. Each participant was assigned a unique ID which linked to the private information such as name, age, address, and phone numbers for follow-ups. All information that could be used to identify participants was coded and stored confidentially.

### 2.5. Role of the funding source

The funding source had no role in either study design, data collection, data analysis or interpretation and drafting the report. The corresponding author have full access to all data obtained from the study and have the final responsibility for publication submission.

### 3. Results

#### 3.1. Clinical and procedural characteristics

Among the 868 patients in the eligible study population, TRI was the dominant access for PCI in our registry (694 patients, 79.9%). Table 1 compares demographic, clinical and procedural characteristics of TRI and TF. Overall, the two target comparison groups had few differences in medical history and procedural characteristics. Patients undergoing TRI were relatively less likely to have previous coronary revascularization such as PCI and CABG (p = 0.024 and p = 0.005). They also tended to have less disease in the left main artery (p < 0.001).

#### 3.2. In-hospital cost and outcomes

The median total hospital costs were 4132 and 5910 USD for patients undergoing TRI and TF in our study (unadjusted cost difference: -1778 USD, approximately 30%). After accounting for baseline differences between the two groups (i.e. history of CABG and PCI, and left main disease), the adjusted difference was -1526.3 USD,
indicating that the cost of TRI is lower than that for TFI by 25.8% (p < 0.001) (Table 2). While health insurance contribution was high (60-70%) in both groups, the out of pocket expenses of participants were 1093 and 1980 USD in TRI and TFI groups, respectively. The majority of in-hospital cost was driven by the particular PCI cost (over 80%) in both groups (Table 2). TRI was associated with higher costs in all particular cost categories such as PCI cost, medication cost, laboratory cost, hospital bed cost and medical supplies cost (p < 0.001). Additionally, patients undergoing TRI were also more likely to have longer LOS, and procedural complications such as major bleeding (p < 0.001).

3.3. Impact of clinical, procedural and outcomes on in-hospital total cost

Procedural characteristics had the largest impact on total hospital cost, including trans-radial PCI, left main disease, PCI with ≥ 2 lesions and PCI with ≥ 2 stents (the standardized coefficients were -0.252; 0.121; 0.156; and 0.417, respectively) (all p < 0.05) (Table 3). Additionally, patient’s age and prior CABG also had an impact on total in-hospital costs (p < 0.05).

3.4. Subgroup analyses

Of 868 patients, the number of patients with ACS and without ACS who underwent PCI was 447 and 421, respectively (Table 4). Results of subgroup analyses by ACS status were consistent with those obtained from the analysis of all subjects. Compared with patients undergoing PCI through TFI, those who received TRI consumed lower in-hospital costs, had a shorter hospital stay and experienced less major bleeding in either ACS or non-ACS (all p < 0.05).

4. Discussion

This study is the first to quantify in-hospital costs and outcomes between TRI and TFI in Vietnam. TRI was significantly associated with a lower cost of 1526.3 USD than TFI (25.8%), a shorter hospital stay and less major bleeding post procedure. The findings are important evidence in PCI cost saving, especially in this lower-middle-income country, where patients endure hardship for healthcare expenses. The result of this study can also contribute to amending clinical practice guidelines and assisting clinicians in making their decisions on the use of PCI.

4.1. In-hospital cost and post procedural outcomes according to the entry sites

Compared with TFI, the use of TRI in PCI practice has received more support partly because it was shown to reduce the bleeding associated with access sites and PCI complications [1,15,16]. Although few studies have investigated cost differences between two different entry sites, among those reporting costs, similar results were reported. Early previous findings reported that TRI was associated with significant reduction in total hospital costs, e.g., up to 15% reduction relative to TFI [17,18]. Recent data, both in countries where TFI has been the dominant access such as the USA, and countries where TRI was more preferred such as China and UK, also confirmed the favourable cost advantage of TRI relative to TFI [5–7,19]. Despite differences in the data analysis approach across
Table 4
Cost and outcomes differences between ACS and non-ACS group.

|                  | TRI    | TFI    | Unadjusted difference (95% CI) | Adjusted difference\(^d\) (95% CI) | P value |
|------------------|--------|--------|---------------------------------|-------------------------------------|---------|
| ACS (n = 447)    |        |        |                                 |                                     |         |
| Total hospital cost (USD\(^c\)) median | 4407.5 | 5422.4 | −1014.9 (-1619.5; -410.3)      | −1257.7 (-1833.6; -681.7)         | <0.0001 |
| Length of stay (day), median | 4.0    | 6.0    | −2.0 (-2.9; -1.1)              | −1.0 (-1.9; -0.1)                 | <0.0001 |
| Major bleeding, n (%) | 3 (0.8) | 8 (9.5) | −8.7 (-15.1; -2.4)             | −8.9 (-15.7; -2.1)                | <0.0001 |
| MACE, n (%)      | 3 (0.8) | 0 (0.0) | -                              | -                                  | >0.9999 |
| Non-ACS (n = 421)|        |        |                                 |                                     |         |
| Total hospital cost (USD\(^c\)) median | 4006.9 | 6159.3 | −2152.4 (-2839.1; -1465.7)     | −1965.2 (-2626.5; -1303.9)        | <0.0001 |
| Length of stay (day), median | 4.0    | 7.0    | −3.0 (-3.9; -2.1)              | −2.0 (-2.9; -1.1)                 | <0.0001 |
| Major bleeding, n (%) | 2 (0.6) | 6 (6.7) | −6.1 (-11.2; -0.8)             | −5.9 (-11.4; -0.5)                | 0.002   |
| MACE, n (%)      | 1 (0.3) | 0 (0.0) | -                              | -                                  | >0.9999 |

ACS: acute coronary syndrome; MACE was the composite of death, myocardial infarction, and coronary revascularisation.
\(^c\) One US dollar is approximately equivalent to 23,350 Vietnam dong (20 June 2019).
\(^d\) Factors adjusted for the difference: previous coronary artery bypass grafts; previous percutaneous coronary intervention; left main disease.

![Fig. 1](image-url) Cost reduction of trans-radial in total hospital cost. Comparison was made between Vietnam, China and USA [5–7].

studies, our findings were concordant with these results, suggesting the finding to be robust. The difference in in-hospital costs for the TRI group in our study was among the highest, compared with other studies in China and USA [5–7] (Figure 1). The characteristics of the two access site groups might be part of the explanation for this difference. Unlike these previous studies, our TFI patient group was likely to have more stents per lesion than the TRI group, probably due to more left main diseases in the former group. This difference subsequently increased the procedure cost, the major component of hospital cost.

The health care system in Vietnam includes both public and private sectors and health care is not free for all people. Our study was conducted in a public hospital where health insurance can cover some components of total expenses that patients incurred in hospital. While health insurance contributed a large proportion of hospital cost of all PCIs (60–70%), the cost difference in out of pocket expenditure was extremely significant in terms of the economic burden on patients, especially given the average monthly income per capita of Northern Vietnamese people was low (approximately 168 USD in 2016) [20]. Depending on the clinical presentation, diagnosis and prognosis of CHD patients, cardiologists will consider the appropriate care and treatment methods, such as PCI or medical therapy. In some very high cost health care such as PCI, the ability to pay might affect the treatment provided, especially in patients with low income and/or no health insurance. Therefore, identifying the in-hospital costs of patients undergoing PCIs using the two access points is an important consideration for future implementing TRI programs.

Regarding post-procedural outcomes in hospital of patients undergoing PCI, similar findings were found in our study. While the reduction advantage of TRI in bleeding complications was reported in most previous studies [5–7,16,21], significant reduction of cardiovascular outcomes such as in-hospital mortality and MACE were also found in TRI group [7,16]. Additionally, patients undergoing TRI in India, China, Australia and USA were found to discharge earlier than their TFI counterparts (from 0.2 day to 2.3 days), which also contribute to the cost reduction [5,7,16,21]. Thus, our findings empirically support the recommendations of recent guidelines on adopting TRI in clinical and add economic evidence to promote the use of this approach in the community practice [22,23].

4.2. Factor associated with hospital cost of patients undergoing PCI

Previous studies reported that the cost saving of TRI was related strongly with a reduced LOS and/or a lower rate of post procedural bleeding complication [6,7,19]. Similar findings were found
in our study. Beside the main component of hospital cost (i.e. PCI costs), other cost differences were seen in terms of hospital bed costs, medication and laboratory tests, which indicated the significant contribution of LOS to the total hospital cost. Thus, to explore the potential effect of other factors associated with total hospital cost, we eliminated LOS in our analysis as LOS seemed to be affected by other factors such as post-procedural complications. The result revealed total hospital cost was likely to be driven mostly by procedural characteristics, especially PCI with > 2 stents and the PCI access sites. This result reinforced the highest contribution of PCI cost to total hospital costs observed in Table 2. Findings from a study in China also supported our study, indicating that total hospital cost differences of PCI patients were related mostly to procedural cost, e.g., vascular closure devices [7], while two studies in USA indicated that the cost saving of TRI was found only in terms of post procedural costs [5,6]. This observation might be explained by the differences in health care systems in Western and Asian countries, which need to be investigated in further studies. Thus, our study reported that the procedural factors such as number of stents per lesion (> 2), PCI access sites having the most impact on the in-hospital cost of patients undergoing PCI. By reporting this finding, we believe that our study made a significant impact on clinical practice of PCI in the country. Even though TRI is the current preferred approach, the valued cost saving of TRI relative to TFI was reported for the first time in a reliable study, which supports the use of this location access in PCI practice at VNHI.

There are some limitations in our study. First, cost data were obtained from the hospital admission system, which can reflect only cost incurred by patients during hospitalization, but not indirect costs such as food supplied or accommodation for the patient’s families who came to care for the patient. Other costs prior to and after discharge was also not investigated. Second, despite adjustment of the cost and outcome differences, selection bias cannot be ruled out due to the nature of non-randomisation of access sites. In fact, most of the participants characteristics are similar between the TRI and TFI group. Another concern is that our data were only derived from the leading cardiac centre in Vietnam, where the highest technology might be applied, then findings might not be considered as representative for the whole nation, but provided important insight of PCI practices. More dedicated studies should be conducted to give full insights of in-hospital cost for the PCI practices in Vietnam.

5. Conclusion

Our study based on the first Vietnamese PCI registry provides an opportunity to understand current insights of in-hospital cost and outcomes of patients undergoing PCI according to entry sites in Vietnam. TRI was the most preferred access site and overall, patients undergoing TRI were associated with lower in-hospital costs, shorter LOS and favourable post-procedural outcomes in comparison with TFI. Procedural factors such as PCI with > 2 stents and PCI access sites had the most impact on in-hospital cost of PCI patients.

Financial support

This research received partial financial support from Curtin University, Australia. The funder had no role in study design, data collection, data analysis and drafting the manuscript for publication.

Declaration of Competing Interest

There is no conflict of interest for all authors.

CRediT authorship contribution statement

Hoa T.T. Vu: Data curation, Formal analysis, Writing - original draft, Conceptualization, Methodology, Supervision. Richard Norman: Writing - review & editing, Supervision. Ngoc M. Pham: Writing - review & editing, Supervision. Hung M. Pham: Conceptualization, Methodology, Supervision. Hoai T.T. Nguyen: Conceptualization, Methodology, Supervision. Quang N. Nguyen: Conceptualization, Methodology, Supervision. Loi D. Do: Conceptualization, Methodology, Supervision. Rachel R. Huxley: Conceptualization, Methodology, Supervision. Crystal M.Y. Lee: Conceptualization, Methodology, Supervision. Tu M. Hoang: Conceptualization, Methodology, Supervision. Christopher M. Reid: Writing - review & editing, Supervision.

Data sharing statement

After publication, the data will be made available to others. All data requests will be considered by the corresponding author for approval. Access to unidentified participant data may be granted following review.

Acknowledgments

We wish to thank the Victorian Cardiac Outcomes Registry for their kind agreement for the adoption of data collection materials, including the abstraction forms and definitions. We wish to also thank the Vietnam Nation Heart Institute for providing us with the opportunity to conduct the pilot registry and the facilities related to the study as well as the patients for participating in the study.

References

[1] Anjum I, Khan MA, Aadil M, Faraz A, Farooqui M, Hashmi A. Transradial vs. transfemoral approach in cardiac catheterization: a literature review. Cureus 2017;9:e1309.
[2] Brueck M, Randorski D, Kramer W, Wieczorek M, Holgten R, Tillmanns H. A randomized comparison of transradial versus transfemoral approach for coronary angiography and angioplasty. Jacc-Cardiocov. Interv. 2009;2:1047–54.
[3] Jolly SS, Yusuf S, Cairns J, et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RI- VALS): a randomised, parallel group, multicentre trial. Lancet 2011;377:1400–20.
[4] Agostini P, Biondi-Zoccai GGL, De Benedictis ML, et al. Radial versus femoral approach for percutaneous coronary diagnostic and interventional procedures - Systematic overview and meta-analysis of randomized trials. J. Am. Coll. Cardiol. 2004;44:349–56.
[5] Safley DM, Amin AP, House JA, et al. Comparison of costs between transradial and transfemoral percutaneous coronary intervention: a cohort analysis from the Premier research database. Am. Heart J. 2013;65:303.
[6] Amin AP, House JA, Safley DM, et al. Costs of transradial versus transcatheter aortic valve implantation. Jacc-Cardiocov. Interv. 2013;6:827–34.
[7] Jin C, Li W, Qiao SB, et al. Costs and benefits associated with transradial versus transfemoral percutaneous coronary intervention in China. J. Am. Heart Assoc. 2016;5;
[8] . Health statistics and information systemsDisease Burden, 2000-2016. World Health Organization; 2017. [Available at: http://www.who.int/healthinfo/global_burden_disease/estimates/en/index1.html Accessed September 12, 2019].
[9] Thomas H, Diamond J, Vieco A, et al. Global atlas of cardiovascular disease 2000-2016: the path to prevention and control. Glob. Heart. 2018;13:143–63.
[10] Gao R. The evolution of percutaneous coronary intervention in Asia: in celebration of the 40th anniversary of percutaneous transluminal coronary angioplasty. Asia Interv. 2017;3:95–6.
[11] Ahn SC, Lee JW, Yun YJ, et al. In-hospital outcome differences between transradial and transfemoral coronary approaches: data from the Korean percutaneous coronary intervention registry. Catheter. Cardiovasc. Interv. 2019.
[12] Vu T, Nguyen T, Pham M, et al. Establishment of a percutaneous coronary intervention registry in Vietnam: rationale and methodology. Global Heart 2020;15:30.
[13] Vu HTT, Pham HM, Nguyen HTT, et al. Novel insights into clinical characteristics and in-hospital outcomes of patients undergoing percutaneous coronary intervention in Vietnam. Int. J. Cardiol. Heart. Vasc. 2020;31:100626.
Ghasemi A, Zahediasl S. Normality tests for statistical analysis: a guide for non-statisticians. Int. J. Endocrinol. Metab. 2012;10:486–9.

[15] Rao SV, Cohen MG, Kandzari DE, Bertrand OF, Gilchrist IC. The transradial approach to percutaneous coronary intervention: historical perspective, current concepts, and future directions. J. Am. Coll. Cardiol. 2010;55:2187–95.

[16] Batra MK, Rai L, Khan NU, et al. Radial or femoral access in primary percutaneous coronary intervention (PCI): Does the choice matter? Indian Heart J. 2020;72:166–71.

[17] Mann T, Cowper PA, Peterson ED, et al. Transradial coronary stenting: comparison with femoral access closed with an arterial suture device. Catheter. Cardiovasc. Interv. 2000;49:150–6.

[18] Mamas M, Tosh J, Hulme W, et al. Economic benefits of transradial percutaneous coronary intervention: a national analysis from the British Cardiovascular Intervention Society database. J. Am. Coll. Cardiol. 2017;70:8178.

[19] Kolb P, Windecker S, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur. J. Cardiothorac. Surg. 2014;46:517–92.